| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arrhythmogenic Right Ventricular Dysplasia | 62 | 2022 | 75 | 10.210 |
Why?
|
| Cardiomyopathies | 33 | 2022 | 167 | 6.710 |
Why?
|
| Amyloid Neuropathies, Familial | 18 | 2022 | 21 | 5.690 |
Why?
|
| Cardiomyopathy, Dilated | 16 | 2023 | 106 | 5.310 |
Why?
|
| Mutation | 44 | 2021 | 1213 | 4.350 |
Why?
|
| Prealbumin | 16 | 2022 | 25 | 3.400 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2021 | 786 | 3.240 |
Why?
|
| Genetic Testing | 21 | 2021 | 159 | 2.870 |
Why?
|
| Heart Failure | 25 | 2022 | 1180 | 2.290 |
Why?
|
| Plakophilins | 16 | 2020 | 19 | 2.220 |
Why?
|
| Phenotype | 36 | 2021 | 947 | 2.060 |
Why?
|
| Marfan Syndrome | 14 | 2015 | 42 | 1.750 |
Why?
|
| Death, Sudden, Cardiac | 14 | 2022 | 141 | 1.740 |
Why?
|
| Amyloid | 6 | 2017 | 39 | 1.520 |
Why?
|
| Humans | 162 | 2023 | 68618 | 1.380 |
Why?
|
| Desmosomes | 7 | 2019 | 14 | 1.360 |
Why?
|
| Amyloidosis | 8 | 2020 | 48 | 1.330 |
Why?
|
| Myocardium | 18 | 2022 | 1204 | 1.270 |
Why?
|
| Arrhythmias, Cardiac | 13 | 2022 | 239 | 1.270 |
Why?
|
| Muscular Dystrophy, Duchenne | 6 | 2018 | 20 | 1.110 |
Why?
|
| Indazoles | 2 | 2022 | 12 | 1.060 |
Why?
|
| Mitral Valve | 6 | 2017 | 166 | 1.060 |
Why?
|
| Middle Aged | 74 | 2023 | 21147 | 1.050 |
Why?
|
| Female | 103 | 2023 | 38074 | 1.040 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 5 | 2012 | 8 | 1.010 |
Why?
|
| Male | 99 | 2023 | 37321 | 0.990 |
Why?
|
| Myocytes, Cardiac | 8 | 2021 | 442 | 0.970 |
Why?
|
| Pedigree | 19 | 2021 | 159 | 0.960 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2016 | 116 | 0.940 |
Why?
|
| Electrocardiography | 20 | 2020 | 601 | 0.930 |
Why?
|
| Benzoxazoles | 7 | 2021 | 12 | 0.920 |
Why?
|
| Heterozygote | 10 | 2018 | 174 | 0.900 |
Why?
|
| Adult | 71 | 2022 | 21403 | 0.900 |
Why?
|
| Ethylenediamines | 1 | 2022 | 5 | 0.850 |
Why?
|
| Tachycardia, Ventricular | 9 | 2022 | 153 | 0.840 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2022 | 5 | 0.840 |
Why?
|
| Mutation, Missense | 5 | 2017 | 112 | 0.840 |
Why?
|
| Heart Valve Diseases | 3 | 2011 | 123 | 0.820 |
Why?
|
| Defibrillators, Implantable | 13 | 2022 | 329 | 0.800 |
Why?
|
| Peripartum Period | 2 | 2021 | 15 | 0.780 |
Why?
|
| Microfilament Proteins | 10 | 2013 | 102 | 0.780 |
Why?
|
| Exome | 2 | 2018 | 20 | 0.770 |
Why?
|
| Connectin | 1 | 2020 | 14 | 0.750 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2017 | 99 | 0.730 |
Why?
|
| RNAi Therapeutics | 1 | 2020 | 3 | 0.730 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2017 | 34 | 0.720 |
Why?
|
| Sarcomeres | 4 | 2018 | 32 | 0.710 |
Why?
|
| Physical Conditioning, Animal | 2 | 2021 | 34 | 0.680 |
Why?
|
| Genetic Counseling | 5 | 2018 | 45 | 0.670 |
Why?
|
| DNA Mutational Analysis | 12 | 2017 | 159 | 0.670 |
Why?
|
| Risk Assessment | 16 | 2020 | 2007 | 0.660 |
Why?
|
| Benzoates | 1 | 2019 | 20 | 0.660 |
Why?
|
| Endocardium | 3 | 2016 | 101 | 0.660 |
Why?
|
| Medical History Taking | 2 | 2019 | 94 | 0.650 |
Why?
|
| Family Health | 4 | 2022 | 83 | 0.630 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 434 | 0.630 |
Why?
|
| Calcium Channel Blockers | 3 | 2015 | 138 | 0.610 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 2 | 2017 | 6 | 0.600 |
Why?
|
| Pyrazoles | 1 | 2019 | 190 | 0.600 |
Why?
|
| Prognosis | 15 | 2022 | 2093 | 0.600 |
Why?
|
| Lamin Type A | 4 | 2022 | 9 | 0.590 |
Why?
|
| Young Adult | 28 | 2021 | 5717 | 0.590 |
Why?
|
| Cell Differentiation | 4 | 2019 | 1034 | 0.580 |
Why?
|
| alpha-Galactosidase | 1 | 2016 | 3 | 0.570 |
Why?
|
| Fabry Disease | 1 | 2016 | 6 | 0.570 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2016 | 5 | 0.570 |
Why?
|
| Risk Factors | 22 | 2022 | 5731 | 0.560 |
Why?
|
| Genetic Variation | 8 | 2021 | 220 | 0.560 |
Why?
|
| Heart Diseases | 4 | 2022 | 276 | 0.560 |
Why?
|
| Aged | 32 | 2020 | 14862 | 0.560 |
Why?
|
| Heart-Assist Devices | 7 | 2020 | 221 | 0.550 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 1 | 0.540 |
Why?
|
| Desmoglein 2 | 6 | 2016 | 7 | 0.540 |
Why?
|
| Transforming Growth Factor beta | 9 | 2013 | 384 | 0.510 |
Why?
|
| Loeys-Dietz Syndrome | 2 | 2013 | 10 | 0.510 |
Why?
|
| Diltiazem | 1 | 2014 | 26 | 0.490 |
Why?
|
| Atrial Fibrillation | 3 | 2013 | 249 | 0.480 |
Why?
|
| Registries | 12 | 2021 | 733 | 0.460 |
Why?
|
| Genomics | 3 | 2018 | 168 | 0.450 |
Why?
|
| Gene Frequency | 5 | 2021 | 207 | 0.440 |
Why?
|
| Animals | 29 | 2022 | 20881 | 0.440 |
Why?
|
| Follow-Up Studies | 22 | 2020 | 3259 | 0.440 |
Why?
|
| Biopsy | 9 | 2020 | 540 | 0.440 |
Why?
|
| Disease Progression | 11 | 2020 | 1038 | 0.430 |
Why?
|
| Heart Transplantation | 7 | 2020 | 328 | 0.430 |
Why?
|
| Aortic Aneurysm | 5 | 2013 | 77 | 0.430 |
Why?
|
| Adolescent | 24 | 2021 | 8912 | 0.430 |
Why?
|
| Stroke Volume | 6 | 2022 | 586 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 15 | 0.420 |
Why?
|
| Ion Channels | 1 | 2012 | 72 | 0.410 |
Why?
|
| Desmoplakins | 6 | 2020 | 14 | 0.410 |
Why?
|
| Penetrance | 3 | 2013 | 17 | 0.410 |
Why?
|
| Heart Ventricles | 8 | 2020 | 738 | 0.400 |
Why?
|
| Retrospective Studies | 24 | 2022 | 7277 | 0.400 |
Why?
|
| Ventricular Fibrillation | 3 | 2018 | 85 | 0.400 |
Why?
|
| Heart Conduction System | 5 | 2017 | 119 | 0.390 |
Why?
|
| Ventricular Function, Right | 3 | 2020 | 103 | 0.380 |
Why?
|
| Consensus | 4 | 2019 | 211 | 0.380 |
Why?
|
| United States | 19 | 2022 | 7367 | 0.380 |
Why?
|
| Cause of Death | 4 | 2020 | 241 | 0.370 |
Why?
|
| Filamins | 2 | 2021 | 17 | 0.370 |
Why?
|
| Exercise | 4 | 2022 | 658 | 0.370 |
Why?
|
| Exercise Tolerance | 3 | 2020 | 75 | 0.370 |
Why?
|
| Disease Models, Animal | 14 | 2019 | 2550 | 0.370 |
Why?
|
| Family | 6 | 2020 | 293 | 0.360 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 301 | 0.360 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 481 | 0.360 |
Why?
|
| Proteins | 1 | 2014 | 474 | 0.360 |
Why?
|
| Fibrillins | 10 | 2013 | 24 | 0.360 |
Why?
|
| Fibrillin-1 | 10 | 2013 | 18 | 0.360 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4848 | 0.360 |
Why?
|
| Myocarditis | 3 | 2019 | 49 | 0.350 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 700 | 0.350 |
Why?
|
| Genotype | 12 | 2021 | 786 | 0.340 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2022 | 277 | 0.340 |
Why?
|
| Mice | 19 | 2022 | 8474 | 0.340 |
Why?
|
| Cadherins | 2 | 2021 | 93 | 0.320 |
Why?
|
| Echocardiography | 9 | 2021 | 515 | 0.310 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 1447 | 0.300 |
Why?
|
| gamma Catenin | 6 | 2016 | 11 | 0.290 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2022 | 101 | 0.290 |
Why?
|
| RNA Splice Sites | 1 | 2006 | 13 | 0.280 |
Why?
|
| Heart | 1 | 2011 | 850 | 0.280 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2008 | 189 | 0.280 |
Why?
|
| Desmocollins | 5 | 2020 | 6 | 0.280 |
Why?
|
| Catheter Ablation | 4 | 2014 | 229 | 0.280 |
Why?
|
| Exercise Test | 3 | 2020 | 242 | 0.280 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 185 | 0.270 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2022 | 119 | 0.260 |
Why?
|
| Predictive Value of Tests | 10 | 2020 | 1465 | 0.260 |
Why?
|
| Cardiomegaly | 1 | 2006 | 213 | 0.250 |
Why?
|
| Treatment Outcome | 14 | 2022 | 7029 | 0.250 |
Why?
|
| Interferon-alpha | 1 | 2005 | 46 | 0.240 |
Why?
|
| Glucagonoma | 1 | 2004 | 3 | 0.240 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2020 | 202 | 0.240 |
Why?
|
| Baltimore | 6 | 2016 | 34 | 0.240 |
Why?
|
| Prevalence | 7 | 2022 | 1619 | 0.240 |
Why?
|
| Primary Prevention | 2 | 2018 | 115 | 0.240 |
Why?
|
| Child, Preschool | 10 | 2015 | 3187 | 0.230 |
Why?
|
| Europe | 3 | 2020 | 196 | 0.230 |
Why?
|
| DNA | 4 | 2014 | 597 | 0.230 |
Why?
|
| Incidence | 9 | 2020 | 1603 | 0.230 |
Why?
|
| Child | 13 | 2019 | 6405 | 0.230 |
Why?
|
| Time Factors | 8 | 2020 | 4655 | 0.220 |
Why?
|
| Losartan | 5 | 2013 | 45 | 0.220 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2022 | 155 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 2 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 58 | 0.210 |
Why?
|
| Troponin I | 2 | 2016 | 34 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 103 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 84 | 0.200 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 40 | 0.200 |
Why?
|
| Amino Acid Sequence | 4 | 2009 | 1083 | 0.200 |
Why?
|
| Netherlands | 3 | 2017 | 68 | 0.200 |
Why?
|
| Skin | 3 | 2017 | 451 | 0.200 |
Why?
|
| Maryland | 3 | 2016 | 77 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1054 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1553 | 0.190 |
Why?
|
| Genetics, Medical | 2 | 2018 | 17 | 0.190 |
Why?
|
| Muscle Contraction | 2 | 2021 | 210 | 0.190 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2011 | 31 | 0.190 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2013 | 95 | 0.190 |
Why?
|
| Electric Countershock | 3 | 2017 | 130 | 0.190 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2019 | 98 | 0.190 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2021 | 10 | 0.190 |
Why?
|
| Age of Onset | 5 | 2015 | 188 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 3 | 2020 | 208 | 0.190 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.190 |
Why?
|
| Rare Diseases | 1 | 2021 | 41 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 2223 | 0.190 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 137 | 0.190 |
Why?
|
| Alleles | 4 | 2021 | 386 | 0.190 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2013 | 56 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 1 | 2004 | 332 | 0.190 |
Why?
|
| Vascular Remodeling | 1 | 2021 | 34 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2011 | 150 | 0.180 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2020 | 13 | 0.180 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 11 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2011 | 147 | 0.180 |
Why?
|
| Diuretics | 1 | 2020 | 97 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 91 | 0.180 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 1140 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1738 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2021 | 94 | 0.180 |
Why?
|
| Calpain | 1 | 2021 | 205 | 0.170 |
Why?
|
| Pregnancy | 5 | 2021 | 2334 | 0.170 |
Why?
|
| Ankyrins | 1 | 2019 | 1 | 0.170 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2019 | 9 | 0.170 |
Why?
|
| Canada | 1 | 2020 | 267 | 0.170 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2013 | 34 | 0.170 |
Why?
|
| Joint Instability | 1 | 2020 | 87 | 0.170 |
Why?
|
| Neutralization Tests | 2 | 2017 | 19 | 0.170 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 79 | 0.170 |
Why?
|
| Cardiomyopathy, Restrictive | 2 | 2009 | 6 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 57 | 0.160 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 258 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2018 | 714 | 0.160 |
Why?
|
| Plectin | 1 | 2018 | 1 | 0.160 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2017 | 86 | 0.160 |
Why?
|
| Statistics as Topic | 2 | 2016 | 219 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 39 | 0.160 |
Why?
|
| Autopsy | 1 | 2018 | 56 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 931 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 438 | 0.160 |
Why?
|
| Aorta | 5 | 2013 | 316 | 0.150 |
Why?
|
| Quality of Life | 4 | 2021 | 1515 | 0.150 |
Why?
|
| Sweden | 1 | 2017 | 21 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 231 | 0.150 |
Why?
|
| Signal Transduction | 6 | 2013 | 2689 | 0.150 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 14 | 0.150 |
Why?
|
| Ventricular Flutter | 1 | 2017 | 1 | 0.150 |
Why?
|
| RNA, Transfer, Leu | 1 | 2017 | 5 | 0.150 |
Why?
|
| Sweat Glands | 1 | 2017 | 10 | 0.150 |
Why?
|
| Genes, Mitochondrial | 1 | 2017 | 4 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 1753 | 0.150 |
Why?
|
| Infant | 7 | 2022 | 2891 | 0.150 |
Why?
|
| Syndrome | 4 | 2013 | 255 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 13 | 0.150 |
Why?
|
| Creatinine | 2 | 2015 | 243 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2017 | 41 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1070 | 0.140 |
Why?
|
| Heart Block | 2 | 2009 | 49 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2017 | 83 | 0.140 |
Why?
|
| Multilevel Analysis | 1 | 2017 | 7 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 536 | 0.140 |
Why?
|
| Nerve Fibers | 1 | 2017 | 77 | 0.140 |
Why?
|
| Prospective Studies | 8 | 2020 | 3705 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 215 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 47 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1174 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2018 | 2358 | 0.140 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 41 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 34 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 506 | 0.140 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 58 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 122 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 3 | 2015 | 247 | 0.140 |
Why?
|
| Membrane Potentials | 1 | 2017 | 200 | 0.140 |
Why?
|
| Pluripotent Stem Cells | 1 | 2017 | 42 | 0.140 |
Why?
|
| Gene Editing | 1 | 2017 | 33 | 0.140 |
Why?
|
| Heparin | 1 | 2017 | 205 | 0.140 |
Why?
|
| Sodium | 1 | 2017 | 161 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 772 | 0.140 |
Why?
|
| Live Birth | 1 | 2015 | 8 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2017 | 230 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2016 | 2673 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 51 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2017 | 326 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 240 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2016 | 144 | 0.130 |
Why?
|
| Angiotensin II | 2 | 2013 | 220 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2018 | 403 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2015 | 38 | 0.130 |
Why?
|
| Desmogleins | 1 | 2015 | 4 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2015 | 30 | 0.130 |
Why?
|
| Cytokines | 1 | 2019 | 866 | 0.130 |
Why?
|
| Survival Rate | 5 | 2017 | 1056 | 0.120 |
Why?
|
| Transfection | 1 | 2017 | 782 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 31 | 0.120 |
Why?
|
| Base Sequence | 2 | 2006 | 1015 | 0.120 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2016 | 117 | 0.120 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2006 | 174 | 0.120 |
Why?
|
| Sulfones | 1 | 2014 | 45 | 0.120 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 1851 | 0.120 |
Why?
|
| Pericardium | 1 | 2014 | 97 | 0.120 |
Why?
|
| Age Factors | 3 | 2022 | 1864 | 0.120 |
Why?
|
| Brugada Syndrome | 1 | 2013 | 5 | 0.120 |
Why?
|
| Sodium Channels | 1 | 2013 | 24 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 546 | 0.120 |
Why?
|
| Cardiology | 1 | 2015 | 140 | 0.110 |
Why?
|
| Zebrafish Proteins | 1 | 2014 | 100 | 0.110 |
Why?
|
| TRPP Cation Channels | 1 | 2013 | 20 | 0.110 |
Why?
|
| Hemodynamics | 2 | 2016 | 705 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 2791 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 138 | 0.110 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2013 | 25 | 0.110 |
Why?
|
| Progeria | 1 | 2013 | 6 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 2014 | 77 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 431 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 157 | 0.110 |
Why?
|
| Hospitalization | 4 | 2021 | 978 | 0.110 |
Why?
|
| Inflammation | 1 | 2019 | 1030 | 0.110 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 4 | 2017 | 61 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2013 | 94 | 0.110 |
Why?
|
| Postmortem Changes | 1 | 2012 | 15 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2012 | 5 | 0.110 |
Why?
|
| Amyloidogenic Proteins | 1 | 2012 | 4 | 0.110 |
Why?
|
| Early Diagnosis | 3 | 2022 | 122 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 206 | 0.110 |
Why?
|
| Giant Cells | 2 | 2016 | 14 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2014 | 312 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 940 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1033 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 710 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 114 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 230 | 0.100 |
Why?
|
| Algorithms | 1 | 2018 | 1196 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.090 |
Why?
|
| Aging | 2 | 2017 | 911 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 214 | 0.090 |
Why?
|
| Infant, Newborn | 4 | 2019 | 2455 | 0.090 |
Why?
|
| Elastic Tissue | 2 | 2007 | 28 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2012 | 597 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 271 | 0.090 |
Why?
|
| Myocardial Contraction | 3 | 2020 | 383 | 0.090 |
Why?
|
| Troponin T | 1 | 2009 | 16 | 0.090 |
Why?
|
| Preconception Care | 1 | 2009 | 14 | 0.090 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 2279 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2014 | 753 | 0.090 |
Why?
|
| Artifacts | 1 | 2010 | 125 | 0.090 |
Why?
|
| Cardiovascular Agents | 2 | 2008 | 82 | 0.090 |
Why?
|
| North America | 1 | 2009 | 112 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2009 | 165 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2019 | 1692 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 951 | 0.080 |
Why?
|
| Heredity | 1 | 2008 | 9 | 0.080 |
Why?
|
| Inheritance Patterns | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cicatrix | 2 | 2022 | 60 | 0.080 |
Why?
|
| Recurrence | 3 | 2020 | 948 | 0.080 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 12 | 0.080 |
Why?
|
| Biomarkers | 4 | 2017 | 1593 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2800 | 0.080 |
Why?
|
| Endocarditis | 1 | 2008 | 14 | 0.080 |
Why?
|
| Fat Necrosis | 1 | 2007 | 2 | 0.080 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 49 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2022 | 242 | 0.080 |
Why?
|
| Vasculitis | 1 | 2007 | 33 | 0.070 |
Why?
|
| Candida glabrata | 1 | 2007 | 3 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 848 | 0.070 |
Why?
|
| Candidiasis | 1 | 2007 | 39 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2006 | 32 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2022 | 140 | 0.070 |
Why?
|
| Indoles | 2 | 2019 | 146 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 145 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 160 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 446 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 458 | 0.070 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2007 | 134 | 0.070 |
Why?
|
| DNA Primers | 1 | 2006 | 302 | 0.070 |
Why?
|
| American Heart Association | 2 | 2017 | 142 | 0.070 |
Why?
|
| Boston | 2 | 2016 | 35 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 317 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2005 | 14 | 0.060 |
Why?
|
| Bone Development | 1 | 2005 | 37 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 284 | 0.060 |
Why?
|
| Skull | 1 | 2005 | 63 | 0.060 |
Why?
|
| Face | 1 | 2005 | 46 | 0.060 |
Why?
|
| Tachycardia, Sinus | 1 | 2004 | 4 | 0.060 |
Why?
|
| Mitral Valve Prolapse | 1 | 2004 | 40 | 0.060 |
Why?
|
| Cardiac Catheterization | 2 | 2020 | 419 | 0.060 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2015 | 10 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2005 | 85 | 0.060 |
Why?
|
| Mice, 129 Strain | 2 | 2013 | 44 | 0.060 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 14 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2013 | 166 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 274 | 0.060 |
Why?
|
| Patient Selection | 2 | 2017 | 592 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 792 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 742 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2022 | 31 | 0.050 |
Why?
|
| Smad2 Protein | 2 | 2013 | 42 | 0.050 |
Why?
|
| Trust | 1 | 2023 | 75 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2004 | 453 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2005 | 342 | 0.050 |
Why?
|
| Fibrosis | 2 | 2015 | 371 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 127 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2015 | 80 | 0.050 |
Why?
|
| Diuresis | 1 | 2020 | 20 | 0.050 |
Why?
|
| Melanoma | 1 | 2005 | 335 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 74 | 0.050 |
Why?
|
| Point Mutation | 1 | 2001 | 97 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 375 | 0.050 |
Why?
|
| Risk | 1 | 2022 | 563 | 0.050 |
Why?
|
| Elastin | 2 | 2012 | 116 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 68 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 136 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 329 | 0.040 |
Why?
|
| Mole Rats | 1 | 2019 | 8 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 149 | 0.040 |
Why?
|
| Polyploidy | 1 | 2019 | 24 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 248 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2019 | 24 | 0.040 |
Why?
|
| Maleimides | 1 | 2019 | 15 | 0.040 |
Why?
|
| Genes, Dominant | 2 | 2013 | 51 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 561 | 0.040 |
Why?
|
| beta Catenin | 1 | 2019 | 73 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2019 | 146 | 0.040 |
Why?
|
| Regeneration | 1 | 2019 | 105 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2003 | 617 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 10 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Genetics | 1 | 2018 | 6 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 195 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2019 | 371 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2018 | 42 | 0.040 |
Why?
|
| Heart Rate | 2 | 2012 | 568 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2012 | 493 | 0.040 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2017 | 2 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.040 |
Why?
|
| Friedreich Ataxia | 1 | 2017 | 6 | 0.040 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 2 | 0.040 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 2 | 0.040 |
Why?
|
| Barth Syndrome | 1 | 2017 | 5 | 0.040 |
Why?
|
| Platelet Factor 4 | 1 | 2017 | 10 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1420 | 0.040 |
Why?
|
| Genome, Human | 1 | 2017 | 62 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 658 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 170 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 45 | 0.040 |
Why?
|
| Myotonic Dystrophy | 1 | 2017 | 19 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cell Shape | 1 | 2017 | 37 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 34 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 696 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 35 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.030 |
Why?
|
| Greece | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 643 | 0.030 |
Why?
|
| Hydralazine | 1 | 2015 | 12 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2015 | 19 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 396 | 0.030 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 11 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2015 | 101 | 0.030 |
Why?
|
| Connexin 43 | 1 | 2016 | 62 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 718 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 31 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2015 | 75 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2015 | 20 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 63 | 0.030 |
Why?
|
| Desmoglein 3 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2015 | 106 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2015 | 33 | 0.030 |
Why?
|
| Child Development | 1 | 2015 | 102 | 0.030 |
Why?
|
| Epicardial Mapping | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1174 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2015 | 38 | 0.030 |
Why?
|
| Protein Folding | 1 | 2015 | 82 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 90 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 329 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2015 | 86 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 711 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 320 | 0.030 |
Why?
|
| Dystrophin | 1 | 2014 | 6 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2015 | 71 | 0.030 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2014 | 30 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2014 | 23 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 39 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2014 | 133 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Electrophysiology | 1 | 2014 | 160 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 190 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 807 | 0.030 |
Why?
|
| Fibroblasts | 2 | 2013 | 902 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 349 | 0.030 |
Why?
|
| Simethicone | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cetrimonium Compounds | 1 | 2013 | 4 | 0.030 |
Why?
|
| Nicotinic Acids | 1 | 2013 | 5 | 0.030 |
Why?
|
| Stearic Acids | 1 | 2013 | 6 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 567 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 249 | 0.030 |
Why?
|
| Myristates | 1 | 2013 | 21 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 32 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2014 | 392 | 0.030 |
Why?
|
| Protein Modification, Translational | 1 | 2013 | 1 | 0.030 |
Why?
|
| Farnesyltranstransferase | 1 | 2013 | 5 | 0.030 |
Why?
|
| Nuclear Envelope | 1 | 2013 | 8 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 204 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 65 | 0.030 |
Why?
|
| Zebrafish | 1 | 2014 | 187 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 160 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 492 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 3 | 0.030 |
Why?
|
| Coronary Vessels | 2 | 2007 | 313 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 181 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 929 | 0.030 |
Why?
|
| Immunoassay | 1 | 2012 | 64 | 0.030 |
Why?
|
| Dopamine | 1 | 2015 | 474 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2013 | 304 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 144 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2012 | 90 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 843 | 0.030 |
Why?
|
| Electrophoresis | 1 | 2012 | 69 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 130 | 0.030 |
Why?
|
| Action Potentials | 1 | 2013 | 223 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 61 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 337 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 498 | 0.020 |
Why?
|
| Diphenylamine | 1 | 2011 | 3 | 0.020 |
Why?
|
| Smad4 Protein | 1 | 2011 | 10 | 0.020 |
Why?
|
| Mortality | 1 | 2012 | 163 | 0.020 |
Why?
|
| Anthracenes | 1 | 2011 | 26 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 368 | 0.020 |
Why?
|
| Aortic Rupture | 1 | 2011 | 32 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2013 | 204 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 86 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 1330 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 507 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 246 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 121 | 0.020 |
Why?
|
| Microfibrils | 1 | 2010 | 2 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 141 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 659 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 330 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1752 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 791 | 0.020 |
Why?
|
| Body Surface Potential Mapping | 1 | 2009 | 10 | 0.020 |
Why?
|
| Mesoderm | 1 | 2010 | 231 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 324 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 595 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2007 | 9 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 184 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2008 | 160 | 0.020 |
Why?
|
| Time | 1 | 2007 | 57 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 164 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 630 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 242 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2009 | 483 | 0.020 |
Why?
|
| Collagen | 1 | 2010 | 636 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 521 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 649 | 0.020 |
Why?
|
| Actins | 1 | 2007 | 249 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 62 | 0.020 |
Why?
|
| Syncope | 1 | 2005 | 23 | 0.020 |
Why?
|
| Propranolol | 1 | 2006 | 103 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 112 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2007 | 211 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 100 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2077 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 241 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2006 | 157 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2006 | 152 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 682 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 43 | 0.020 |
Why?
|
| Systole | 1 | 2004 | 149 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2006 | 175 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 161 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2324 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2003 | 15 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1040 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 2003 | 13 | 0.010 |
Why?
|
| Glucuronidase | 1 | 2003 | 11 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 174 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2006 | 318 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 286 | 0.010 |
Why?
|
| Siblings | 1 | 2003 | 34 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 166 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 235 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 1451 | 0.010 |
Why?
|
| Neoplasms | 1 | 2013 | 1667 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 849 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 770 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|